Literature DB >> 24848264

The urokinase plasminogen activator receptor (uPAR) controls macrophage phagocytosis in intestinal inflammation.

Marco Genua1, Silvia D'Alessio2, Javier Cibella2, Alessandro Gandelli2, Emanuela Sala2, Carmen Correale2, Antonino Spinelli3, Vincenzo Arena4, Alberto Malesci1, Sergio Rutella4, Victoria A Ploplis5, Stefania Vetrano2, Silvio Danese2.   

Abstract

OBJECTIVE: Inflammation plays crucial roles in the pathogenesis of several chronic inflammatory disorders, including Crohn's disease (CD) and UC, the two major forms of IBD. The urokinase plasminogen activator receptor (uPAR) exerts pleiotropic functions over the course of both physiological and pathological processes. uPAR not only has a key role in fibrinolysis but also modulates the development of protective immunity. Additionally, uPAR supports extracellular matrix degradation and regulates cell migration, adhesion and proliferation, thus influencing the development of inflammatory and immune responses. This study aimed to evaluate the role of uPAR in the pathogenesis of IBD.
DESIGN: The functional role of uPAR was assessed in established experimental models of colitis. uPAR deficiency effects on cytokine release, polarisation and bacterial phagocytosis were analysed in colonic macrophages. uPAR expression was analysed in surgical specimens collected from normal subjects and patients with IBD.
RESULTS: In mice, uPAR expression is positively regulated as colitis progresses. uPAR-KO mice displayed severe inflammation compared with wild-type littermates, as indicated by clinical assessment, endoscopy and colon histology. The absence of uPAR led to an increased production of inflammatory cytokines by macrophages that showed an M1 polarisation and impaired phagocytosis. In human IBD, CD68(+) macrophages derived from the inflamed mucosa expressed low levels of uPAR.
CONCLUSIONS: These findings point to uPAR as an essential component of intestinal macrophage functions and unravel a new potential target to control mucosal inflammation in IBD. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Bacterial Translocation; Experimental Colitis; Integrins; Macrophages; Molecular Mechanisms

Mesh:

Substances:

Year:  2014        PMID: 24848264     DOI: 10.1136/gutjnl-2013-305933

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  13 in total

1.  Plasmin and plasminogen induce macrophage reprogramming and regulate key steps of inflammation resolution via annexin A1.

Authors:  Michelle A Sugimoto; Ana Luíza C Ribeiro; Bruno R C Costa; Juliana P Vago; Kátia M Lima; Fernanda S Carneiro; Mylena Maira O Ortiz; Graziele Letícia N Lima; Aline A F Carmo; Renata M Rocha; Denise A Perez; Alessandra C Reis; Vanessa Pinho; Lindsey A Miles; Cristiana C Garcia; Mauro M Teixeira; Lirlândia P Sousa
Journal:  Blood       Date:  2017-03-20       Impact factor: 22.113

2.  Association of the Circulating Supar Levels with Inflammation, Fibrinolysis, and Outcome in Severe Burn Patients.

Authors:  Jian-Chang Lin; Xiao-Dong Chen; Zhao-Rong Xu; Lin-Wen Zheng; Zhao-Hong Chen
Journal:  Shock       Date:  2021-12-01       Impact factor: 3.454

Review 3.  Plasminogen activator receptor assemblies in cell signaling, innate immunity, and inflammation.

Authors:  Steven L Gonias
Journal:  Am J Physiol Cell Physiol       Date:  2021-08-18       Impact factor: 5.282

4.  Epithelial and stromal cell urokinase plasminogen activator receptor expression differentially correlates with survival in rectal cancer stages B and C patients.

Authors:  Seong Beom Ahn; Charles Chan; Owen F Dent; Abidali Mohamedali; Sun Young Kwun; Candice Clarke; Julie Fletcher; Pierre H Chapuis; Edouard C Nice; Mark S Baker
Journal:  PLoS One       Date:  2015-02-18       Impact factor: 3.240

5.  Serum suPAR and syndecan-4 levels predict severity of community-acquired pneumonia: a prospective, multi-centre study.

Authors:  Qiongzhen Luo; Pu Ning; Yali Zheng; Ying Shang; Bing Zhou; Zhancheng Gao
Journal:  Crit Care       Date:  2018-01-24       Impact factor: 9.097

6.  Transcriptomic pathway analysis of urokinase receptor silenced breast cancer cells: a microarray study.

Authors:  Pavan B Narayanaswamy; Tapan K Baral; Hermann Haller; Inna Dumler; Kshitish Acharya; Yulia Kiyan
Journal:  Oncotarget       Date:  2017-09-28

7.  Plasminogen and the Plasminogen Receptor, Plg-RKT, Regulate Macrophage Phenotypic, and Functional Changes.

Authors:  Juliana P Vago; Michelle A Sugimoto; Kátia M Lima; Graziele L Negreiros-Lima; Nagyung Baik; Mauro M Teixeira; Mauro Perretti; Robert J Parmer; Lindsey A Miles; Lirlândia P Sousa
Journal:  Front Immunol       Date:  2019-06-28       Impact factor: 7.561

8.  High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma.

Authors:  Sven H Loosen; Frank Tacke; Niklas Püthe; Marcel Binneboesel; Georg Wiltberger; Patrick H Alizai; Jakob N Kather; Pia Paffenholz; Thomas Ritz; Alexander Koch; Frank Bergmann; Christian Trautwein; Thomas Longerich; Christoph Roderburg; Ulf P Neumann; Tom Luedde
Journal:  Carcinogenesis       Date:  2019-08-22       Impact factor: 4.944

9.  SerpinB2 inhibits migration and promotes a resolution phase signature in large peritoneal macrophages.

Authors:  Wayne A Schroder; Thiago D Hirata; Thuy T Le; Joy Gardner; Glen M Boyle; Jonathan Ellis; Eri Nakayama; Dilan Pathirana; Helder I Nakaya; Andreas Suhrbier
Journal:  Sci Rep       Date:  2019-08-27       Impact factor: 4.379

10.  Serum levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of colorectal liver metastases.

Authors:  Sven H Loosen; Frank Tacke; Marcel Binnebosel; Catherine Leyh; Mihael Vucur; Florian Heitkamp; Wenzel Schoening; Tom F Ulmer; Patrick H Alizai; Christian Trautwein; Alexander Koch; Thomas Longerich; Christoph Roderburg; Ulf P Neumann; Tom Luedde
Journal:  Oncotarget       Date:  2018-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.